ATXS: Astria Therapeutics Inc Kompaniya qiymatining sof foydaga nisbati
Astria Therapeutics (ATXS) joriy savdo daromadlarisiz faoliyat yuritmoqda va o'z tadqiqotlarini moliyalashtirish uchun investitsiya kapitaliga tayanadi. Kompaniya kam uchraydigan patologiyalar uchun noyob davolash usullarini ishlab chiqmoqda va klinik sinovlarda raqobatchilardan ustun bo'lishni maqsad qilgan. Antitanachlar ishlab chiqilishi AQShda amalga oshiriladi, ishlab chiqarish esa uchinchi tomon pudratchilariga topshirilgan. Narxlar dinamikasida aks etgan bozor holati P/E ko'rsatkichi -5.70 ekanligini ko'rsatmoqda.
%20P%2FE%20multiplikatori&width=1200&height=400&colorIndex=0&v=mwhdatcg.m7-7dqbc3k&start=20220704&end=20261115&filename=GURU_Markets_-_ATXS_-_Astria-Therapeutics_-_PE-Multiple "ATXS: Astria Therapeutics Biznesning o‘zini qoplash muddati 04.07.2022 - 07.02.2026 | 👁️GURU.Markets👁️")
Astria Corp (ATXS) kompaniyasining tahliliy kesimlari
- narx va narxlar bo'yicha konsensus prognoz:
- bozor kapitallashuvi haqida ma'lumot:
- buxgalteriya balansi bo'yicha sof aktivlar qiymati ko'rsatkichlari:
- qarzlar va to'lov qobiliyati haqida ma'lumot:
Umumiy qarzning xususiy kapitalga nisbati Astria Therapeutics|ATXS - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzning kapitalga nisbati astriatx.com|ATXS - Kompaniya qarzlari|Qarzning balans qiymatiga nisbati Astria Therapeutics Inc|ATXS - Kompaniyaning uzoq muddatli qarzlari|Qisqa muddatli qarz Astria Therapeutics|Tezkor likvidlik koeffitsiyenti astriatx.com
- foyda va bozor multiplikatorlari tafsilotlari:
ATXS - Kompaniyaning sof foydasi|Kompaniya foydasi prognozi Astria Therapeutics|ATXS - Narx-foyda koeffitsiyenti|Kapitalizatsiyaning kelajakdagi foydaga nisbati Astria Corp|ATXS - Narxning foydaga va o‘sish sur’atiga nisbati|Biznes qiymatining amortizatsiya chegirilishidan oldingi operatsion foydaga nisbati Astria Therapeutics Inc|ATXS - EBITDA operatsion foydasi|So'nggi to'rtta chorak uchun bir aksiya uchun sof foyda Astria Therapeutics|ATXS - Bir aksiya uchun sof foyda (EPS TTM)|Choraklik EPS foyda o'sishi astriatx.com|ATXS - Bu yil bir aksiya uchun sof foyda o'sishi|Keyingi yilda bir aksiya uchun foydaning kutilayotgan dinamikasi Astria Therapeutics
- realizatsiya hajmi va tushum ko'rsatkichlari:
Kompaniyaning har tomonlama tahlili:Astria Therapeutics, Inc. ATXS
Kamyob kasalliklarga e'tibor qaratadigan biofarmatsevtika sektori uchun P/E ko'rsatkichi bozor kapitalizatsiyasini biznesning haqiqiy daromadliligiga solishtirish vositasi bo'lib xizmat qiladi. -5.70 ga teng bo'lgan joriy P/E baholash darajasi aksiya narxining aksiya uchun sof foydaga nisbatini aks ettiradi. Ushbu ko'rsatkich STAR-0215 dori vositasining kelgusidagi muvaffaqiyati uchun to'langan premiumni baholash imkonini beradi. Astria Therapeutics (ATXS) kompaniyasining fundamental jozibadorligi bu yerda M&A salohiyati va yangi dozalash protokollarining samaradorligi bilan belgilanadi.
Muhim raqobatchilar
P/E multiplikatori Argenx|Narx-foyda koeffitsiyenti BNTX (BioNTech Group)|ABVX (abivax.com) - Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori ADMA (admabiologics.com)|Biznesning o‘zini qoplash muddati protagonist-inc.com (PTGX)|IMVT - Narxning foydaga nisbati|Kiniksa Pharmaceuticals, Ltd. (KNSA) - Narx-foyda koeffitsiyenti|Grifols Biemat (GRFS) - Narxning foydaga nisbati|Narx-foyda koeffitsiyenti Adaptive Biotechnologies|Narx-foyda koeffitsiyenti CLDX|P/E multiplikatori auriniapharma.com|Narxning foydaga nisbati BioCryst Pharmaceuticals Inc (BCRX)|Vera Therapeutics - Narx-foyda multiplikatori|P/E multiplikatori DNTH (dianthustx.com)|Pharvaris Pharma (PHVS) - Kapitalizatsiyaning foydaga nisbati|AbCellera Biologics - P/E multiplikatori|tourmalinebio.com - Bozor narxining sof foydaga nisbati|Precigen (PGEN) - Narxning foydaga nisbati|Pharming Group - Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Nektar Therapeutics Inc|UPB (Upstream Pharma) - Bozor narxining sof foydaga nisbati|P/E multiplikatori ZBIO|P/E multiplikatori immunome.com (IMNM)|P/E multiplikatori GOSS (gossamerbio.com)|Biznesning o‘zini qoplash muddati KalVista Pharma (KALV)|SEPN - Narxning foydaga nisbati|Biznesning o‘zini qoplash muddati Pieris Pharmaceuticals PVLA|SVRA (Savara Inc.) - Narx-foyda koeffitsiyenti|Kapitalizatsiyaning sof foydaga nisbati RIGL (Rigel Pharmaceuticals)|ANAB (AnaptysBio) - P/E multiplikatori|ENGN: Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati RAPT Therapeutics (RAPT)|JBIO (Aerovate) - Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori ACRS (Aclaris Therapeutics)|Kompaniya qiymatining sof foydaga nisbati KYTX|Tiziana Life Sciences - P/E multiplikatori|CABA: Narxning foydaga nisbati|VTYX: P/E multiplikatori|THTX (Theratechnologies, Inc) - Narxning foydaga nisbati|AVTX (Avalo Therapeutics, Inc.) - P/E multiplikatori|P/E multiplikatori Eledon Pharmaceuticals|Narxning foydaga nisbati Agenus Inc. (AGEN)|Narx-foyda koeffitsiyenti Climb Bio Inc. CLYM|P/E multiplikatori ZURA (Zura Bio Ltd)|ATYR - Narx-foyda koeffitsiyenti|ADAG - Narxning foydaga nisbati|IMA - P/E multiplikatori|STTK: P/E multiplikatori|Equillium Bio (EQ) - P/E multiplikatori|CNTB (connectbiopharm.com) - P/E multiplikatori|IMUX: Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori ATRA|P/E multiplikatori InflaRx NV (IFRX)|X4 Pharmaceuticals, Inc. (XFOR) - Kapitalizatsiyaning sof foydaga nisbati|P/E multiplikatori adicetbio.com ACET|Celularity - P/E multiplikatori|Kompaniya qiymatining sof foydaga nisbati INMB (INmune Bio Corp)|BRNS (Barinthus Bio) - Narx-foyda koeffitsiyenti|Kapitalizatsiyaning sof foydaga nisbati KZR (Kezar Life Sciences)|Narxning foydaga nisbati SAB Biotherapeutics Inc.|Akari Therapeutics Plc - Kapitalizatsiyaning sof foydaga nisbati|Narx-foyda koeffitsiyenti ENLV (Enlivex Therapeutics Ltd.)|Narx-foyda koeffitsiyenti Q32 Bio Inc QTTB|Narxning foydaga nisbati geovax.com GOVX|P/E multiplikatori edesabiotech.com EDSA|iBio Corporation - P/E multiplikatori|Kompaniya qiymatining sof foydaga nisbati CARM (carismatx.com)|XTL Biopharmaceuticals Ltd. (XTLB) - Narxning foydaga nisbati|Bolt Bio (BOLT) - P/E multiplikatori|HCWB (HCW Biologics Inc) - P/E multiplikatori|Narx-foyda koeffitsiyenti Aptevo Therapeutics (APVO)|P/E multiplikatori AIM|Bozor narxining sof foydaga nisbati ADTX|P/E multiplikatori GRI (GRI Bio Corporation)|P/E multiplikatori XORTX Corp XRTX|HIND - Narxning foydaga nisbati|Revelation Biosciences (REVB) - Narx-foyda koeffitsiyenti|INDP (Indaptus Therapeutics, Inc.) - Narx-foyda koeffitsiyenti|Scinai Immunotherapeutics Ltd (SCNI) - P/E multiplikatori|CALI (CalciMedica Inc) - P/E multiplikatori|affimed.com - Kapitalizatsiyaning sof foydaga nisbati|Narxning foydaga nisbati allakos.com (ALLK)|P/E multiplikatori HOOKIPA Pharma, Inc. (HOOK)|IGM Biosciences Inc. - Narx-foyda koeffitsiyenti|iTeos Therapeutics, Inc. (ITOS) - Kapitalizatsiyaning foydaga nisbati|OCEA: Narx-foyda koeffitsiyenti|Kompaniya qiymatining sof foydaga nisbati TCBP (TC BioPharm (Holdings) PLC)|THRD: P/E multiplikatori
